This continuing medical education activity is provided by
This activity is supported by an educational grant from Genentech, Inc.
The intended audience for the activity is family practitioners, general practitioners, internists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Upon successful completion of this activity, participants should be better able to:
- Utilize diagnostic assays for influenza that have demonstrated sensitivity, specificity, and convenience.
- Examine the mechanisms of action, efficacy, and safety of conventional and new antiviral agents used to treat influenza.
- Incorporate antiviral therapies into practice for prophylaxis, prevention, and treatment of influenza to reduce the duration of illness as well as complications.
Influenza places a substantial burden on the health of people in the United States each year, despite its variable impact. However, an unmet need exists for better and more rapid diagnostic modalities as well as antiviral therapies that can effectively treat an infection to minimize the risk of complications. In this continuing medical education activity, expert faculty will discuss diagnostic modalities as well as the current and emerging therapies for treating patients with influenza.
Michael G. Ison, MD, MS, FIDSA, FAST
Professor, Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Medical Director, Transplant and Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Consulting Fee: Celltrion, Genentech/Roche, Janssen, Seqirus, Shionogi, Toyama/MediVector, Vir Biotechnology
Contracted Research: Beckman Coulter, Cepheid, Chimerix, Emergent BioScience, Gilead, Janssen, Shire
Data Safety & Monitoring Board: GlaxoSmithKline, Shionogi
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur
Flu in Motion: Case Presentation
Charles P. Vega, MD, FAAFP
Clinical Professor of Family Medicine
Associate Dean for Diversity and Inclusion
University of California, Irvine
Santa Ana, CA
Consulting Fee: Genentech
Reviewers report the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttests and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly for each video. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™, (0.25 per video). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn up to 0.75 MOC points (0.25 per video) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
This enduring material is approved for 1 year from the date of original release, September 30, 2019 to September 29, 2020.
MIPS Qualifying Activity
Completion of this accredited CME activity meets the expectations of an Accredited Safety or
Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Participants who successfully complete the activity and its performance assessment will receive
printable documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP, accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
- Baloxavir Prescribing Information
- 2018 Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza
- Seasonal Influenza Vaccine Effectiveness, 2004-2018
- Influenza Antiviral Medications: Summary for Clinicians
- FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses
- Information for Clinicians on Influenza Virus Testing
- What You Should Know About Influenza (Flu) Antiviral Drugs
- Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
- Influenza Antiviral Drug Resistance
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Contact us at CME@VindicoCME.com